Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: Potential relevance for treatment outcome

Therapeutic Drug Monitoring

Volumn 35, Issue 4, 2013, Pages 546-551

  Van Vlerken, Lotte G ^a   De Kanter, Clara T M M ^b   Boland, Greet J ^a   Van Loon, Anton M ^a   Van Soest, Hanneke ^a   Koek, Ger H ^c   Drenth, Joost P H ^b   Siersema, Peter D ^a   Van Erpecum, Karel J ^a   Burger, David M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

chronic hepatitis C; pharmacokinetics; ribavirin; TDM; therapeutic drug monitoring

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; STEADY STATE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84880572168     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828a9fbf     Document Type: Article

References (29)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
2. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2004;20:931-938.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
4. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993-999.
5. Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C a critical review. Ann Pharmacother. 2009;43:2044-2063.
6. Maynard M, Pradat P, Gagnieu MC, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther. 2008;13:607-611.
7. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62:1174-1180.
8. Stanke-Labesque F, Loustaud-Ratti V, Babany G, et al. Ribavirin therapeutic drug monitoring: why, when and how? Fundam Clin Pharmacol. 2010;24:401-406.
9. van Vlerken LG, Huisman EJ, van SH, et al. Ribavirin rather than PEGinterferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients. J Viral Hepat. 2012;19:39-46.
10. Morello J, Rodriguez-Novoa S, Cantillano AL, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit. 2007;29: 802-806.
11. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555-565.
12. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999; 19:17-24.
13. Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, et al. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit. 2011;33:40-44.
14. van Soest H, van der Schaar PJ, Koek GH, et al. No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis. 2010;42:496-502.
15. D'Avolio A, Ibanez A, Sciandra M, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835:127-130.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
17. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008;47:1453-1461.
18. Weiss JJ, Brau N, Stivala A, et al. Review article: adherence to medication for chronic hepatitis C building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther. 2009;30:14-27.
19. Wade JR, Snoeck E, Duff F, et al. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006;62:710-714.
20. D'Avolio A, Ciancio A, Siccardi M, et al. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirinassociate anemia in patients receiving standard anti-HCV treatment. Ther Drug Monit. 2012;34:165-170.
21. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
22. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
23. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
24. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.
25. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-2428.
26. Marquet P, Sauvage FL, Loustaud-Ratti V, et al. Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. Ther Drug Monit. 2010;32:237-241.
27. Craxi A. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264.
28. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
29. Zeuzem S. Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons? J Hepatol. 2004;41:488-490.